These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37153146)

  • 1.
    Li D; Huang X; Rao H; Yu H; Long S; Li Y; Zhang J
    Front Cell Infect Microbiol; 2023; 13():1157010. PubMed ID: 37153146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.
    Kohler PP; Volling C; Green K; Uleryk EM; Shah PS; McGeer A
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1319-1328. PubMed ID: 28950924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
    Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
    J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.
    Yang CC; Wu CH; Lee CT; Liu HT; Chen JB; Chiu CH; Chen CH; Chuang FR
    Int J Infect Dis; 2014 Nov; 28():3-7. PubMed ID: 25200093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
    Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
    BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
    Brizendine KD; Richter SS; Cober ED; van Duin D
    Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
    Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and mortality for elderly patients with bloodstream infection of carbapenem resistance Klebsiella pneumoniae: a 10-year longitudinal study.
    Chen Y; Chen Y; Liu P; Guo P; Wu Z; Peng Y; Deng J; Kong Y; Cui Y; Liao K; Huang B
    BMC Geriatr; 2022 Jul; 22(1):573. PubMed ID: 35831805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
    Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
    Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Carbapenem-resistant
    Wang Z; Qin RR; Huang L; Sun LY
    Chin Med J (Engl); 2018 Jan; 131(1):56-62. PubMed ID: 29271381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: A systematic review and meta-analysis.
    Li D; Rao H; Xu Y; Zhang M; Zhang J; Luo J
    J Infect Chemother; 2024 May; 30(5):372-378. PubMed ID: 38369125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes.
    Mouloudi E; Massa E; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Piperidou M; Orphanou A; Passakiotou M; Imvrios G; Fouzas I; Papanikolaou V; Gritsi-Gerogianni N
    Transplant Proc; 2014 Nov; 46(9):3216-8. PubMed ID: 25420863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.
    Ariffin H; Navaratnam P; Mohamed M; Arasu A; Abdullah WA; Lee CL; Peng LH
    Int J Infect Dis; 2000; 4(1):21-5. PubMed ID: 10689210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality-related factors in patients with OXA-48 carbapenemase-producing Klebsiella pneumoniae bacteremia.
    Rodríguez OL; Sousa A; Pérez-Rodríguez MT; Martínez-Lamas L; Suárez RL; Martínez CT; Pino CP; Vidal FV; Pérez-Landeiro A; Casal MC
    Medicine (Baltimore); 2021 Apr; 100(14):e24880. PubMed ID: 33832068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
    Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
    Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant Klebsiella pneumoniae acquisition in lung transplant recipients.
    Raviv Y; Shitrit D; Amital A; Fox B; Bakal I; Tauber R; Bishara J; Kramer MR
    Clin Transplant; 2012; 26(4):E388-94. PubMed ID: 22882693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China.
    Li Y; Li J; Hu T; Hu J; Song N; Zhang Y; Chen Y
    Antimicrob Resist Infect Control; 2020 Jun; 9(1):79. PubMed ID: 32487221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.